What's Going On With Capricor Therapeutics Stock On Friday?
Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference
Caprock Announces Closing of Private Placement
Early Warning Press Release - Frank Guillemette Announces Completion of Acquisition of Common Shares of Caprock Mining Corp.
Caprock Announces Proposed Private Placement
Caprock Announces Consistent High-Grade Intercepts from the Final Three Deep Drill Holes at Destiny, Including 8.32 g/t Au over 2.6m
Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy
Capricor Therapeutics, Inc. (CAPR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Capricor Therapeutics to Present at Upcoming Investor Conferences
Capricor: I Rate It A Buy After Stress-Testing The Sell Thesis
Capricor Therapeutics, Inc. (CAPR) Q1 2026 Earnings Call Transcript
Capricor Therapeutics Q1 Earnings Call Highlights
Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Capricor's Insider Just Sold Big — Her Options Tell the rest of the Story
Capricor Therapeutics Says NS Pharma Delays Could Threaten Access To Duchenne Therapy
Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12
Capricor Therapeutics (NASDAQ:CAPR) CFO Anthony Bergmann Sells 25,000 Shares of Stock
Capricor Therapeutics (NASDAQ:CAPR) Director Karimah Es Sabar Sells 61,265 Shares
Capricor Therapeutics (NASDAQ:CAPR) Director Karimah Es Sabar Sells 53,735 Shares of Stock
Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above 50 Day Moving Average – What’s Next?
Contrasting Zimmer Biomet (NYSE:ZBH) and Capricor Therapeutics (NASDAQ:CAPR)
Capricor: Moving To 'Buy' Rating As New PDUFA Date Is Set For Deramiocel
Capricor Therapeutics Stock Slides As Q4 Earnings Miss Estimates
Capricor Therapeutics, Inc. (CAPR) Q4 2025 Earnings Call Transcript
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy
Capricor Therapeutics Stock Jumps As FDA Resumes Deramiocel Review
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday?
GSA Capital Partners LLP Makes New $1.56 Million Investment in Capricor Therapeutics, Inc. $CAPR
CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February
Maravai LifeSciences (NASDAQ:MRVI) & Capricor Therapeutics (NASDAQ:CAPR) Critical Review
Here's Why This Biotechnology Skyrocketed by 439% in December
Capricor Therapeutics (NASDAQ:CAPR) versus Glucose Health (OTCMKTS:GLUC) Head to Head Survey
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript
Caprock Provides Update on Drilling and Announces Expansion of Drill Program at Its Destiny Gold Project
Caprock Announces Closing of Private Placement and Confirmation of Payment of Anniversary Payment on Destiny Option
Martin Shkreli's Biotech Short Position Is Blowing Up As Stock Soars 440%: Momentum Score Spikes
Capricor: Maintaining 'Hold' Rating On Randomized Phase 3 HOPE-3 Trial Win With Deramiocel
Biotech Stocks To Add to Your Watchlist – December 5th
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript
CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know
Caprock Announces Proposed Private Placement
Capricor Therapeutics Announces Proposed Public Offering of Common Stock
Martin Shkreli touts QCLS stock as a long idea after a “bad call” on CAPR
Capricor Stock Soars, Shkreli Is Short: Here's What Pharma Bro Had To Say
Biotech Stock Up Over 400% After Late-Stage Breakthrough
Capricor Therapeutics Duchenne Treatment Shows Strong Heart And Muscle Results In Trial